Skip to main content
SpringerLink
Log in

General Chemotherapy Imaging

  • Chapter
  • First Online:
Atlas of Genitourinary Oncological Imaging

Part of the book series: Atlas of Oncology Imaging ((AOI,volume 1))

  • 2289 Accesses

Abstract

Toxicity assessments on patients undergoing chemotherapy or targeted molecular therapy are performed regularly by the referring oncologist. Some toxicities have radiologic manifestations (see Table 7.1). Occasionally, the radiologist is asked by the oncologist to assess for a clinically suspected toxicity that has an associated radiologic presentation. An example of this is bleomycin-induced pulmonary toxicity encountered during the treatment of metastatic germ cell tumor of the testis. Some classic chemotherapy agents and particularly the newer targeted therapies have toxicities with radiologic manifestations that are asymptomatic [1]. Therefore the radiologist may be the first to detect these toxicities. A summary of the treatment options and radiographic presentations of the more common side effects encountered during treatment of genitourinary tumors is presented here.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Torrisi JM, Schwartz LH, Gollub MJ, et al. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 2011;258:41–56.

    Article  PubMed  Google Scholar 

  2. Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist. 2010;15:236–45.

    Article  PubMed  CAS  Google Scholar 

  3. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.

    Article  PubMed  CAS  Google Scholar 

  4. Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist. 2010;15:104–11.

    Article  PubMed  CAS  Google Scholar 

  5. Bukowski RM. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2010;10:635–45.

    Article  PubMed  CAS  Google Scholar 

  6. Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int. 2009;104:1585–9.

    Article  PubMed  CAS  Google Scholar 

  7. RECORD-1 Study Group, Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256–65.

    Article  PubMed  CAS  Google Scholar 

  8. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8.

    Article  PubMed  CAS  Google Scholar 

  9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.

    Article  PubMed  CAS  Google Scholar 

  10. Escudier B, Eisen T, Stadler WM, et al. TARGET Study Group. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.

    Google Scholar 

  11. Escudier B, Pluzanska A, Koralewski P, et al. for the AVOREN Trial investigators. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11.

    Google Scholar 

  12. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422–8.

    Article  PubMed  CAS  Google Scholar 

  13. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.

    Article  PubMed  CAS  Google Scholar 

  14. Rock EP, Goodman V, Jiang JX, et al. Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12:107–13.

    Article  PubMed  CAS  Google Scholar 

  15. Eklund JW, Kuzel TM. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. Cancer Treat Res. 2005;126:263–87.

    Article  PubMed  Google Scholar 

  16. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Saf. 1992;7:417–33.

    Article  PubMed  CAS  Google Scholar 

  17. Davis SD, Berkmen YM, Wang JC. Interleukin-2 therapy for advanced renal cell carcinoma: radiographic evaluation of response and complications. Radiology. 1990;177:127–31.

    PubMed  CAS  Google Scholar 

  18. Saxon RR, Klein JS, Bar MH, et al. Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients. AJR Am J Roentgenol. 1991;156:281–5.

    Article  PubMed  CAS  Google Scholar 

  19. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13:1084–96.

    Article  PubMed  CAS  Google Scholar 

  20. Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly—a ­mini-review. Gerontology. 2010;56:303–9.

    Article  PubMed  CAS  Google Scholar 

  21. Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011;59:526–40.

    Article  PubMed  Google Scholar 

  22. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–24.

    Article  PubMed  CAS  Google Scholar 

  23. St Peter SD, Abbas MA, Kelly KA. The spectrum of pneumatosis intestinalis. Arch Surg. 2003;138:68–75.

    Article  PubMed  Google Scholar 

  24. White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010;182:396–403.

    Article  PubMed  Google Scholar 

  25. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer. 2006;42:1875–80.

    Article  PubMed  CAS  Google Scholar 

  26. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010;60:244–72.

    Article  PubMed  Google Scholar 

  27. Babjuk M. Current value of neoadjuvant chemotherapy prior to cystectomy. Eur Urol. 2010;9(Suppl):424–7.

    Google Scholar 

  28. Sternberg CN, Calabro F. Adjuvant chemotherapy for bladder cancer. Expert Rev Anticancer Ther. 2005;5:987–92.

    Article  PubMed  CAS  Google Scholar 

  29. Flechon A, Droz JP. Chemotherapy practices and perspectives in invasive bladder cancer. Expert Rev Anticancer Ther. 2006;6:1473–82.

    Article  PubMed  CAS  Google Scholar 

  30. Morgan TM, Clark PE. Bladder cancer. Curr Opin Oncol. 2010;22:242–9.

    Article  PubMed  Google Scholar 

  31. Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol. 2006;33:98–105.

    Article  PubMed  CAS  Google Scholar 

  32. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008;133:528–38.

    Article  PubMed  CAS  Google Scholar 

  33. Vander Els NJ, Stover DE. Chemotherapy-induced lung disease. Clin Pulm Med. 2004;11:84–91.

    Article  Google Scholar 

  34. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80:286–91.

    Article  PubMed  CAS  Google Scholar 

  35. Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf. 2008;7:703–16.

    Article  PubMed  CAS  Google Scholar 

  36. Shahab N, Haider S, Doll DC. Vascular toxicity of antineoplastic agents. Semin Oncol. 2006;33:121–38.

    Article  PubMed  CAS  Google Scholar 

  37. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160(6 Pt 1):2021–4.

    PubMed  CAS  Google Scholar 

  38. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008;299:672–84.

    Article  PubMed  CAS  Google Scholar 

  39. van den Belt-Dusebout AW, de Wit R, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25:4370–8.

    Article  PubMed  Google Scholar 

  40. Yoon GH, Stein JP, Skinner DG. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle. Expert Rev Anticancer Ther. 2005;5:75–85.

    Article  PubMed  Google Scholar 

  41. Cordier JF. Cryptogenic organising pneumonia. Eur Respir J. 2006;28:422–6.

    Article  PubMed  Google Scholar 

  42. Kawai K, Akaza H. Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer. Expert Opin Drug Saf. 2003;2:587–96.

    Article  PubMed  CAS  Google Scholar 

  43. Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18:2169–78.

    PubMed  CAS  Google Scholar 

  44. Cantwell BM, Mannix KA, Roberts JT, et al. Thromboembolic events during combination chemotherapy for germ cell-malignancy. Lancet. 1988;2:1086–7.

    Article  PubMed  CAS  Google Scholar 

  45. Vos AH, Splinter TA, van der Heul C. Arterial occlusive events during chemotherapy for germ cell cancer. Neth J Med. 2001;59:295–9.

    Article  PubMed  CAS  Google Scholar 

  46. Cheng E, Berthold DR, Moore MJ, Duran I. Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors. Acta Oncol. 2009;48:475–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 136 Mountain View Boulevard, Basking Ridge, NJ, 07920, USA

    Jean M. Torrisi M.D.

  2. Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Tunc A. Iyriboz M.D.

  3. Department of Medicine, Memorial Sloan-Kettering Cancer Center at Basking Ridge, 136 Mountain View Boulevard, Basking Ridge, NJ, 07920, USA

    Han Xiao M.D.

Authors
  1. Jean M. Torrisi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tunc A. Iyriboz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Han Xiao M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean M. Torrisi M.D. .

Editor information

Editors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, Department of Radiology, York Avenue 1275, New York, 10065, New York, USA

    Ariadne M Bach

  2. Memorial Sloan-Kettering Cancer Center, Department of Radiology, York Avenue 1275, New York, 10065, New York, USA

    Jingbo Zhang

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Torrisi, J.M., Iyriboz, T.A., Xiao, H. (2013). General Chemotherapy Imaging. In: Bach, A., Zhang, J. (eds) Atlas of Genitourinary Oncological Imaging. Atlas of Oncology Imaging, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4872-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4872-3_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-4871-6

  • Online ISBN: 978-1-4614-4872-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation